2020-06-15
It is with great pleasure to welcome Pål Falck as a CBO for Oncorena, starting September 1, 2020. Pål brings a breadth of relevant experience and competence to strengthen our leadership in time for the exciting next development steps of Oncorena.
Pål joins us from Arctic Securities AS, Oslo where is was en Equity Research Analyst covering Healthcare. Before that he has been with Pfizer and AstraZeneca in medical assignments, including Medical Director and Scout for external opportunities, covering Oncology and other therapeutic areas.
Pål is trained as a pharmacist from University of Oslo and he has a Ph.D. in an area of great relevance to Oncorena, – pharmacokinetics and renal transplantation. He has also a degree as Executive Master of Management. BI, from Norwegian Business School.
Please, join me in congratulating Pål to his new appointment!
Lars Grundemar, M.D., Ph.D.
Chief Executive Officer
Oncorena AB
2023-11-22
In 2011, the pharmaceutical company Oncorena was founded with the mission to develop a breakthrough treatm…
Read more2023-10-06
Oncorena is adding a new member to the team - Åsa Holmgren is appointed Head of Regulatory Affairs. With a…
Read more2023-09-06
Susanna Dahlgren now joins Oncorena as Chief Operating Officer, having supported the company for approxima…
Read more